ArticlePloS one2014
Artesunate abolishes germinal center B cells and inhibits autoimmune arthritis.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 56 citations in OpenAlex.
- Review
- Network pharmacology-based strategy to investigate the mechanisms of artemisinin in treating primary Sjögren's syndrome.BMC immunology · 2024Article
- Advances in the study of artemisinin and its derivatives for the treatment of rheumatic skeletal disorders, autoimmune inflammatory diseases, and autoimmune disorders: a comprehensive review.Frontiers in immunology · 2024Review
- Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3-mediated N6-methyladenosine modification of ICAM2 mRNA in fibroblast-like synoviocytes.Clinical and translational medicine · 2022Article
- Discovery and repurposing of artemisinin.Frontiers of medicine · 2022Review
- New Insights into Artesunate as a Pleiotropic Regulator of Innate and Adaptive Immune Cells.Journal of immunology research · 2022Review
- Natural medicines of targeted rheumatoid arthritis and its action mechanism.Frontiers in immunology · 2022Review
- 9,10-Anhydrodehydroartemisinin Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Th1 and Th17 Cell Differentiation.Inflammation · 2021Article
- The Germinal Center Milieu in Rheumatoid Arthritis: The Immunological Drummer or Dancer?International journal of molecular sciences · 2021Review
- Role of Artesunate on cardiovascular complications in rats with type 1 diabetes mellitus.BMC endocrine disorders · 2021Article
- Research Progress on Artemisinin and Its Derivatives against Hematological Malignancies.Chinese journal of integrative medicine · 2020Review
- A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients.Arthritis research & therapy · 2019Article
- cGAS-mediated control of blood-stage malaria promotes Plasmodium-specific germinal center responses.JCI insight · 2018Article
- Novel natural product therapeutics targeting both inflammation and cancer.Chinese journal of natural medicines · 2017Review
- Spontaneous germinal centers and autoimmunity.Autoimmunity · 2017Review
- Immune suppressive properties of artemisinin family drugs.Pharmacology & therapeutics · 2016Review
- Artesunate Ameliorates Experimental Autoimmune Encephalomyelitis by Inhibiting Leukocyte Migration to the Central Nervous System.CNS neuroscience & therapeutics · 2016Article
- Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation.Cellular & molecular immunology · 2016Article
- The Potential Therapeutic Effects of Artesunate on Stroke and Other Central Nervous System Diseases.BioMed research international · 2016Review
- Updates on artemisinin: an insight to mode of actions and strategies for enhanced global production.Protoplasma · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The antimalarial drug artemisinin and its derivatives exhibit potent immunosuppressive activity in several autoimmune disease models, however the mechanisms are not well-understood. This study was designed to investigate the therapeutic effects and the underlying mechanisms of the artemisinin analog artesunate using the K/BxN mouse model of rheumatoid arthritis. The well-studied disease mechanisms of K/BxN model allowed us to pinpoint the effect of artesunate on disease. Artesunate treatment prevented arthritis development in young K/BxN mice by inhibiting germinal center (GC) formation and production of autoantibodies. In adult K/BxN mice with established arthritis, artesunate diminished GC B cells in a few days. However, artesunate did not affect the follicular helper T cells (Tfh). In contrast to the spontaneous K/BxN model, artesunate treatment exerted minor influence on K/BxN serum transfer induced arthritis suggesting that artesunate has minimal effect on inflammatory responses downstream of antibody production. Finally, we showed that artesunate preferentially inhibits proliferating GC B cells. These results identify GC B cells as a target of artesunate and provide a new rationale for using artemisinin analogues to treat autoimmune diseases mediated by autoantibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.